Markets:

Overview

News

Currencies

International

Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

108.46 -0.05 (-0.05%)

Official Closing Price Updated: 7:00 PM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

8 Analysts Have This to Say About Glaukos ↗

September 26, 2023

Via Benzinga

Glaukos Announces Participation in Wells Fargo Healthcare Conference

August 23, 2023

From Glaukos Corporation

Via Business Wire

Glaukos Announces Second Quarter 2023 Financial Results

August 02, 2023

From Glaukos Corporation

Via Business Wire

Glaukos's Earnings Outlook ↗

August 01, 2023

Via Benzinga

Analyst Ratings for Glaukos ↗

July 31, 2023

Via Benzinga

Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst ↗

July 19, 2023

Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside...

Via Benzinga

Where Glaukos Stands With Analysts ↗

July 14, 2023

Via Benzinga

Stifel Maintains Buy Rating for Glaukos: Here's What You Need To Know ↗

June 26, 2023

Via Benzinga

8 Analysts Have This to Say About Glaukos ↗

June 26, 2023

Via Benzinga

Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.

July 17, 2023

From Glaukos Corporation

Via Business Wire

These 2 Soaring Stocks Finished the Week Strong ↗

July 14, 2023

Wall Street coasted into the close on Friday but still had a good week.

Via The Motley Fool

UnitedHealth, Elanco Animal Health And Other Big Stocks Moving Higher On Friday ↗

July 14, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023

July 12, 2023

From Glaukos Corporation

Via Business Wire

Analyst Expectations for Glaukos's Future ↗

June 05, 2023

Via Benzinga

Glaukos: Q1 Earnings Insights ↗

May 03, 2023

Via Benzinga

Expert Ratings for Glaukos ↗

April 18, 2023

Via Benzinga

Glaukos Poised for $1B in Sales by 2030: Piper Sandler Predicts With Stock Upgrade ↗

June 07, 2023

Piper Sandler has upgraded Glaukos Corporation (NYSE: GKOS) to Overweight from a Neutral ra

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023 ↗

June 07, 2023

Via Benzinga

Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)

June 05, 2023

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in the William Blair Growth Stock Conference

May 24, 2023

From Glaukos Corporation

Via Business Wire

Tyson Foods, PayPal And 3 Stocks To Watch Heading Into Monday ↗

May 08, 2023

With US stock futures trading slightly lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Glaukos Announces FDA Acceptance of NDA Submission for iDose TR

May 05, 2023

From Glaukos Corporation

Via Business Wire

Glaukos Announces First Quarter 2023 Financial Results

May 03, 2023

From Glaukos Corporation

Via Business Wire

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting

May 01, 2023

From Glaukos Corporation

Via Business Wire

Glaukos Announces the Release of its 2022 Sustainability Report

April 19, 2023

From Glaukos Corporation

Via Business Wire

Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3

April 12, 2023

From Glaukos Corporation

Via Business Wire

Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It ↗

March 09, 2023

Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.

Via Benzinga

Glaukos Submits New Drug Application to U.S. FDA for iDose TR

February 27, 2023

From Glaukos Corporation

Via Business Wire

NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday ↗

February 23, 2023

Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose...

Via Benzinga

Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

From Glaukos Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.